Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 389, Issue 10, pp 1133–1137 | Cite as

Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic

  • Jiesheng Kang
  • David R. Compton
  • Roy J. Vaz
  • David Rampe
Brief Communication

Abstract

Loperamide is a μ-opioid receptor agonist commonly used to treat diarrhea and often available as an over-the-counter medication. Recently, numerous reports of QRS widening accompanied by dramatic QT interval prolongation, torsades de pointe arrhythmia, and death have been reported in opioid abusers consuming large amounts of the drug to produce euphoria or prevent opiate withdrawal. The present study was undertaken to determine the mechanisms of this cardiotoxicity. Using whole-cell patch clamp electrophysiology, we tested loperamide on the cloned human cardiac sodium channel (Nav1.5) and the two main repolarizing cardiac K+ channels cloned from the human heart: KvLQT1/minK and the human ether-a-go-go-related gene (hERG) channel. Loperamide inhibited Nav1.5 with IC50 values of 297 and 239 nM at holding potentials of −90 and −70 mV, respectively. Loperamide was weakly active on KvLQT1/minK producing 17 and 65 % inhibition at concentrations of 1 and 10 μM, respectively. Conversely, loperamide was found to be a very high affinity inhibitor of the hERG channel with an IC50 value of 89 nM at room temperature and 33 nM when measured at physiological temperature. The QRS and QT interval prolongation and the attending arrhythmias, produced by loperamide, derive from high affinity inhibition of Nav1.5 and especially hERG. Since the drug has been widely available and safely used as directed for many years, we believe that the potent inhibition loperamide possesses for cardiac ion channels has only been uncovered because of the excessive misuse of the drug as a consequence of the recent opioid abuse epidemic.

Keywords

Loperamide hERG Torsades de pointe KvLQT1/minK Nav1.5 Arrhythmia Abuse Opioid 

References

  1. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G (1996) K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature 384:78–80CrossRefPubMedGoogle Scholar
  2. Cools F, Benatar A, Bruneel E, Theyskens C, Bougatef A, Casteels A, Vandenplas Y (2003) A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants. Eur J Clin Pharmacol 59:17–22PubMedGoogle Scholar
  3. Daniulaityte R, Carlson R, Falck R, Cameron D, Perera S, Chen L, Sheth A (2013) ‘I just want to tell you that loperamide WILL WORK’; a web-based study of extra-medical use of loperamide. Drug Alcohol Depend 130:241–244. doi: 10.1016/j.drugalcdep.2012.11.003 CrossRefPubMedGoogle Scholar
  4. Eggleston W, Clark KH, Marraffa JM (2016) Loperamide abuse associated with cardiac dysrhythmia and death. Ann Emerg Med. doi: 10.1016/j.annemergmed.2016.03.047 PubMedGoogle Scholar
  5. Enakpene EO, Bin Riaz I, Shirazi FM, Raz Y, Indik JH (2015) The long QT teaser: loperamide abuse. Am J Med 128:1083–1086. doi: 10.1016/j.amjmed.2015.05.018 CrossRefPubMedGoogle Scholar
  6. FDA (2016) Drug Safety Communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm504617.htm
  7. Gellens ME, George AL Jr, Chen LQ, Chahine M, Horn R, Barchi RL, Kallen RG (1992) Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proc Natl Acad Sci U S A 89:554–558CrossRefPubMedPubMedCentralGoogle Scholar
  8. Harmer AR, Valentin JP, Pollard CE (2011) On the relationship between block of the cardiac sodium channel and drug-induced prolongation of the QRS complex. Br J Pharmacol 164:260–273. doi: 10.1111/j.1476-5381.2011.01415.x CrossRefPubMedPubMedCentralGoogle Scholar
  9. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR (1993) Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513–1518CrossRefPubMedGoogle Scholar
  10. Kang J, Chen X-L, Wang L, Rampe D (2001) Interactions of the antimalrial drug mefloquine with the human cardiac potassium channels KvLQT1/mink and HERG. J Pharmacol Exp Ther 299:290–296PubMedGoogle Scholar
  11. Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC, Shyjka LM, Lacerda AE, Brown AM (2004) Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 50:93–101. doi: 10.1016/j.vascn.2004.06.003 CrossRefPubMedGoogle Scholar
  12. Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D (2000) Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 295:614–620PubMedGoogle Scholar
  13. Marraffa JM, Holland MG, Sullivan RW, Morgan BW, Oakes JA, Wiegand TJ, Hodgman MJ (2014) Cardiac conduction disturbances after loperamide abuse. Clin Toxicol 52:952–957. doi: 10.3109/15563650.2014.969371 CrossRefGoogle Scholar
  14. Pearlstein R, Vaz R, Rampe D (2003) Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem 46:2017–2022. doi: 10.1021/jm0205651 CrossRefPubMedGoogle Scholar
  15. Persson PB (2016) Opiate of the masses. Acta Physiol 217:270–271. doi: 10.1111/alpha.12736 CrossRefGoogle Scholar
  16. Rampe D, Brown AM (2013) A history of the role of the hERG channel in cardiac risk assessment. J Pharmacol Toxicol Methods 68:13–22. doi: 10.1016/j.vascn.2013.03.005 CrossRefPubMedGoogle Scholar
  17. Rampe D, Roy ML, Dennis A, Brown AM (1997) A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 417:28–32CrossRefPubMedGoogle Scholar
  18. Regnard C, Twycross R, Mihalyo M, Wilcock A (2011) Loperamide. J Pain Symptom Manage 42:319–323. doi: 10.1016/j.jpainsymman.2011.06.001 CrossRefPubMedGoogle Scholar
  19. Sanguinetti MC, Jiang C, Curran ME, Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299–307CrossRefPubMedGoogle Scholar
  20. Spinner HL, Lonardo NW, Mulamalla R, Stehlik J (2015) Ventricular tachycardia associated with high-dose chronic loperamide use. Pharmacotherapy 35:234–238. doi: 10.1002/phar.1540 CrossRefPubMedGoogle Scholar
  21. Wightman RS, Hoffman RS, Howland MA, Rice B, Biary R, Lugassy D (2016) Not your regular high: cardiac dysrhythmia caused by loperamide. Clin Toxicol 54:454–458. doi: 10.3109/15563650.2016.1159310 CrossRefGoogle Scholar
  22. Wishart DS, Knox C, Guo AC, Shrivastata S, Hassanali M, Sothard P, Chang Z, Woolsey J (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668–D672. doi: 10.1093/nar/gjk067, Database issueCrossRefPubMedGoogle Scholar
  23. Yap YG, Camm AJ (1999) Arrhythmogenic mechanisms of non-sedating antihistamines. Clin Exp Allergy 29(suppl 3):174–181CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Jiesheng Kang
    • 1
  • David R. Compton
    • 2
  • Roy J. Vaz
    • 3
  • David Rampe
    • 2
  1. 1.Preclinical SafetySanofi, IncWalthamUSA
  2. 2.Preclinical SafetySanofi, IncBridgewaterUSA
  3. 3.Lead Generation and Compound RealizationSanofi, IncWalthamUSA

Personalised recommendations